The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

Early COVID suppression could have prevented 180,000 UK deaths, study reveals … FDA, CDC pause chikungunya vaccine for adults ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty answers questions about the ...

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...

There are still no vaccines for most neglected tropical diseases. Read more at straitstimes.com. Read more at ...

Measles cases have once again doubled in Manitoba.The province reported on its website Wednesday that 24 new cases had been ...